- Home
- KDK vs ZYME Comparison
KDK vs ZYME Comparison
Compare KDK & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KDK | ZYME |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | KDK | ZYME |
|---|---|---|
| Price | $5.32 | $26.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $15.38 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.5M | 625.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $236.00 | $183.10 |
| Revenue Next Year | $459.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $5.00 | $11.86 |
| 52 Week High | $11.35 | $29.75 |
Technical Indicators
Market Signals| Indicator | KDK | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 62.38 |
| Support Level | N/A | $22.44 |
| Resistance Level | $9.38 | $26.75 |
| Average True Range (ATR) | 0.37 | 1.10 |
| MACD | 0.01 | 0.39 |
| Stochastic Oscillator | 25.62 | 79.83 |
Price Performance
Historical ComparisonAbout KDK Kodiak AI Inc.
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.